Methods and compositions relating to treatment of pulmonary arterial hypertension

Abstract

The technology described herein is directed to methods and compositions for the treatment of hypertension, e.g. pulmonary arterial hypertension, relating to inhibition of TGFβ1, TGFβ3, and/or GDF-15.

1 . A method of treating hypertension or fibrosis in a subject in need of treatment thereof, the method comprising administering an inhibitor of GDF-15; TGFβ1; and/or TGFβ3 to the subject. 
     
     
         2 . The method of  claim 1 , wherein the hypertension is pulmonary arterial hypertension (PAH). 
     
     
         3 . The method of  claim 1 , wherein the subject is a subject having or diagnosed as having pulmonary arterial hypertension (PAH). 
     
     
         4 . The method of  claim 1 , wherein the fibrosis is fibrosis associated with a disease or condition selected from the group consisting of:
 emphysema; COPD; interstitial lung disease and pulmonary fibrosis; idiopathic pulmonary fibrosis; scleroderma lung disease; interstitial or pulmonary vascular disease; bleomycin induced lung injury; pulmonary fibrosis due to exposure to chemotherapeutic drugs (methotrexate, cyclophosphamide) or other toxins; chronic lung disease associated with prematurity, a.k.a., bronchopulmonary dysplasia; pulmonary fibrosis or interstitial lung disease associated with exposure to antiarrhythmic drugs (e.g. amiodarone); and interstitial lung disease associated with exposure to asbestos, silica, or grain.   
     
     
         5 . The method of  claim 1 , wherein the subject is a subject having or diagnosed as having a disease or condition selected from the group consisting of:
 emphysema; COPD; interstitial lung disease and pulmonary fibrosis; idiopathic pulmonary fibrosis; scleroderma lung disease; interstitial or pulmonary vascular disease;   bleomycin induced lung injury; pulmonary fibrosis due to exposure to chemotherapeutic drugs (methotrexate, cyclophosphamide) or other toxins; chronic lung disease associated with prematurity, a.k.a., bronchopulmonary dysplasia; pulmonary fibrosis or interstitial lung disease associated with exposure to antiarrhythmic drugs (e.g. amiodarone); and interstitial lung disease associated with exposure to asbestos, silica, or grain.   
     
     
         6 . The method of  claim 1 , wherein the inhibitor inhibits TGFβ1. 
     
     
         7 . The method of  claim 1  any of  claims 1   5 , wherein the inhibitor inhibits TGFβ3. 
     
     
         8 . The method of  claim 1 , wherein the inhibitor inhibits TGFβ1 and TGFβ3. 
     
     
         9 . The method of  claim 1 , wherein the inhibitor inhibits GDF15. 
     
     
         10 . The method of  claim 9 , wherein the inhibitor further inhibits TGFβ1 and/or TGFβ3. 
     
     
         11 . The method of  claim 1 , wherein the inhibitor is specific for GDF15. 
     
     
         12 . The method of  claim 1 , wherein the inhibitor is specific for TGFβ1. 
     
     
         13 . The method of  claim 1 , wherein the inhibitor is specific for TGFβ3. 
     
     
         14 . The method of  claim 1 , wherein the inhibitor is an antibody reagent or ligand trap. 
     
     
         15 . The method of  claim 14 , wherein the ligand trap is a TGFβ-1/3 GDF-15 ligand trap. 
     
     
         16 . The method of  claim 15 , wherein the ligand trap is TGFBRII-Fc. 
     
     
         17 . The method of  claim 1 , wherein the subject has scleroderma or connective tissue disease associated with PAH (APAH-CTD). 
     
     
         18 . The method of  claim 1 , wherein the subject is determined to have an increased level of GDF-15, TGFβ1, and/or TGFβ3 relative to a control. 
     
     
         19 . The method of  claim 18 , wherein the subject is determined to have an increased level of GDF-15, TGFβ1, and/or TGFβ3 relative to the average level of GDF-15, TGFβ1, and/or TGFβ3 in subjects having PAH but not showing symptoms of scleroderma or APAH-CTD.